Results 121 to 130 of about 34,211 (250)

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundThis study evaluates the efficacy of various pharmacological therapies in mitigating the cardiotoxicity associated with anthracycline chemotherapy and furnishes contemporary, evidence-based guidelines and recommendations for clinical practice ...
Xiaoyu Liu, Ran Ding, Aihua Zhang
doaj   +1 more source

Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

, 2004
Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles after bolus dosing that resemble continuous infusion of conventional anthracyclines, increased drug concentrations in tumor ...
Dibella, Nicholas J, Sparano, Joseph A, Jahanzeb, Mohammad, Rivera, Edgardo, Venook, Alan P, Stewart, Simon J, Gabizon, Alberto A, Muggia, Franco M, Carmichael, James, Alberts, David S, Kavanagh, John J, Winer, Eric P, Skubitz, Keith M   +12 more
core   +1 more source

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline‐Induced Cardiotoxicity Using an Integrated PK/PD Model

Clinical and Translational Science
Doxorubicin (DOX) is an effective chemotherapeutic agent; however, its use is limited by dose‐dependent cardiotoxicity, which is challenging to detect early with current biomarkers such as NT‐proBNP.
Mohamed S. Dabour, Anne H. Blaes, Pamala A. Jacobson, Mark N. Kirstein, Beshay N. Zordoky, Shen Cheng   +5 more
doaj   +1 more source

Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium

British Journal of Haematology, EarlyView.
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana, Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Estelle Borgne, Anne‐Charlotte de Grande, Audrey Sarry, Ziyad Acheaibi, Laetitia Largeaud, Morgane Sighieri, Emilie Klein, Emmanuelle Tavernier, Marie‐Anne Hospital, Martin Carré, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz   +22 more
wiley   +1 more source

Chapter 19: Anthracyclines and Liver Function

, 2015
In this chapter, Dr. Benjamin describes studies he did to show that anthracyclines could be successfully used to treat cancer patients with compromised liver function.https://openworks.mdanderson.org/mchv_interviewchapters/1547/thumbnail ...
Benjamin, Robert S., PhD, Rosolowski, Tacey A., PhD   +1 more
core  

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Medroxyprogesterone acetate increases anthracyclines uptake in chronic lymphatic cells: Role of nitric oxide and lipid peroxidation

, 2000
Anthracyclines are one of the most used drugs in the therapy of several malignant tumors. Unfortunately its use is still limited by their cardio-toxicity and by the presence of cancer cells resistant to these drugs.
CRISPINO A., PAGNINI G., PACILIO C., GIORDANO A., PAGNINI U., FLORIO S., CLAUDIO P. P.   +6 more
core   +1 more source